Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
- International PhD Programme (IPP) Mainz
- University of Oslo
- ;
- Ghent University
- Karolinska Institutet
- Technical University of Denmark
- University of Nottingham
- ; University of East Anglia
- ; University of Leeds
- ; University of Nottingham
- Leibniz Institute for Plasma Science and Technology
- SciLifeLab
- University of British Columbia
- University of Warsaw
- Uppsala University
- ; Newcastle University
- ; Swansea University
- ; The University of Manchester
- ; University of Bradford
- ; University of Glasgow
- ; University of Plymouth
- ; University of Southampton
- ; University of Sussex
- ; University of Warwick
- Aalborg University
- Amsterdam UMC
- Baylor College of Medicine
- Campus Bio-Medico University
- Curtin University
- ETH Zurich
- Heidelberg University
- Ilya Pharma
- KNAW
- KTH Royal Institute of Technology
- KU Leuven (Coordinator)
- Lunds universitet
- NTNU - Norwegian University of Science and Technology
- Nature Careers
- Newcastle University
- Norwegian University of Life Sciences (NMBU)
- Royal Netherlands Academy of Arts and Sciences (KNAW)
- Rutgers University
- Swansea University
- Technische Universität Darmstadt
- The Netherlands Cancer Institute
- The Ohio State University
- The University of Chicago
- The University of Iowa
- Umeå University
- University College Dublin
- University Medical Centre Groningen (UMCG)
- University of Adelaide
- University of Amsterdam
- University of Copenhagen
- University of Crete
- University of Galway
- University of Houston
- University of Lund
- University of Maryland, Baltimore
- University of Montpellier
- University of Pittsburgh
- University of Southern California
- University of Utah
- Uppsala universitet
- 54 more »
- « less
-
Field
-
Primary supervisor - Dr Amit Sachdeva Secondary supervisor - Prof Andy Cammidge Over the last decade, several antibody-based biotherapeutics have been developed for treatment of cancer
-
BCL-2 family proteins. An imbalance in this complex interplay of the BCL-2 family can result in unrestricted cell proliferation. Due to its anti- apoptotic function, many cancers become dependent on BCL
-
, named bioportides, are also biologically active and can themselves act as a drug. Of relevance to this project, selected bioportides which mimic important segments of proteins found throughout the animal
-
) are engineered proteins that can serve as substitute antibodies in the immune system. Due to their high potential in e.g. cancer treatment, they attract enormous attention from pharmaceutical industry. At the same
-
are regulated in their own unique way in response to cellular stress, during differentiation, and in cancer. Current data on tRNA genes and models for regulation of protein coding genes do not provide
-
of four years of full-time doctoral education is required. The research group The doctoral studies will be conducted in the Cancer proteomics Mass spectrometry (MS) research group headed by professor Janne
-
differentiation, and in cancer. Current data on tRNA genes and models for regulation of protein coding genes do not provide an explanation for the observed dynamics in the expression of tRNA genes. In
-
the immune system, but cancer cells overproduce proteins which turn off the immune system. Two of the proteins which control this are Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1). Being able
-
equality and diversity as a strength and an asset. Job description and work duties Monoclonal antibodies (mAbs) are engineered proteins that can serve as substitute antibodies in the immune system. Due
-
proteins and how immune cells in our body fight against disease using their protein repertoire. Our work has important applications, especially in understanding immune cells better and finding new ways